Bonum Certa Men Certa

Pharma Patents Have Become Harder to Enforce, So IAM Together With the Patent Microcosm Sets Up Lobbying Events

IAM: When "alternative facts" are up for sale (if one can afford them)

Battistelli and IAM



Summary: The difficulty associated with enforcing certain types of patents (more so after Mayo and ۤ 101) means that litigious attitudes and reliance on law firms are decreasing; IAM strikes back with another one of its many lobbying events (designed to shape public opinion and influence key decision-makers)

THE concept of patents is pretty much universal, but not all patents are created equal. There are different sorts of patents ("families") pertaining to or belonging to different domains. Speaking of them all as though they're the same is the recipe for meaningless debates. Not all patents, for example, are a matter of life or death. Ethical aspects apply in some cases; sometimes pure economics.



"Not all patents, for example, are a matter of life or death."As we discovered quite recently, EPO oppositions can crash companies. In other words, wrong decisions (or intentions) to grant can be truly harmful and pretty awful to workers. Things get pretty freaky when patents are being claimed on life itself. Forward Pharma lost 30% of its value (or valuation) in just one day at the end of January. This was due to an EPO decision. Yes, some sectors are over-reliant on patents; there's no question about it. Here's an example from two days ago: (in the UK)

Shares in Scancell Holdings PLC rose sharply on Friday morning as the company said its Moditope immunotherapy platform is to be granted a European patent.

Scancell shares were up 11% on Friday at 13.54 pence per share.


How good is this European Patent (EP)? Well, there's lack of certainty under Battistelli, so Scancell Holdings PLC might be the next Forward Pharma (a one-day collapse).

"What we have here is a cross-continental fight taken up to the ITC and failing, having heavily relied on a patent from the USPTO."Pacific Biosciences is meanwhile attempting to 'compete' by causing embargo of its rival, Oxford Nanopore. We wrote about it some days ago and received plenty of comments from people involved in this matter. It's yet another one of those ITC examples where patent litigation is geared towards embargoes and bankruptcies, not innovation. Here is what the face-saving press release said (striving to justify waste of shareholders' money, spent on litigation). This campaign of patent litigation by Pacific Biosciences backfired pretty badly. "Pacific Bio down 2% premarket on ITC patent ruling," Wall Street media stated shortly thereafter. To quote: "The ITC interpreted the term "single-molecule sequencing" as limited to sequencing-by-synthesis approaches, determining that Oxford's sequencing approach is not "single-molecule sequencing.""

What we have here is a cross-continental fight taken up to the ITC and failing, having heavily relied on a patent from the USPTO.

We have become increasingly supportive of the USPTO because it continues to deny patents on life and even software patents. PTAB helps and gravitates towards that. See the latest PTAB Life Sciences Report by John Cravero and Pharma Patents Blog writing about 35 U.S.C. ۤ 101 rejections (not just based on Alice but also Mayo):

We’ve written previously about ex parte decisions of the Patent Trial and Appeal Board (PTAB) affirming patent eligibility rejections that seem to be inconsistent with the USPTO’s Subject Matter Eligibility Guidance. Apparently, applicants should be wary about appealing any rejection of a diagnostic method claim, because the PTAB may enter sua sponte patent eligibility rejections even if the examiner did not make a €§ 101 rejection.


Aside from ۤ 101 there's also 35 U.S.C. ۤ 102. Hospira, based on this blog post, wins again. MedCo's patent has been declared bogus as per ۤ 102. To quote:

In the litigation, Hospira argued both (1) that the MedCo patents were invalid and (1) that Hospira’s proposed generic Angiomax drug would not infringe. The district court sided with MedCo on the first point (patents not invalid) but with Hospira on the second (patents not infringed). On appeal, the Federal Circuit has affirmed the non-infringement ruling but reversed on the on sale issue. The interesting portion is the on sale question.


Benjamin Anger and Jacob R. Rosenbaum wrote about it some days ago (very detailed).

"They get what they paid for. It's pure lobbying/marketing."As one can expect, the litigation 'industry' isn't particularly happy about that. Many patents are being invalidated, which must be causing decrease in demand for patents and lawsuits (their main "offerings" or "services" or "products").

There's a "Pharma and Biotech IP Summit" being organised by IAM and as one can expect, the bill for this lobbying event is being footed by the main participants. "Finnegan is a Gold sponsor of IAM Magazine," it says. There's therefore a paid-for 'talk' (marketing). This not only helps Finnegan control the 'debate'; it also keeps IAM on their 'good side' (maybe IAM will give Finnegan some more of these bogus 'rewards' or 'endorsements'). "Jen Roscetti will present "The View from the United States" at @IAM_magazine's #Pharma and #Biotech #IP Summit in London," Finnegan wrote the other day. They get what they paid for. It's pure lobbying/marketing.

"Either way, "Pharma and Biotech IP Summit" is an IAM sham. It's sponsored by and dominated by the patent microcosm."With all honesty, more people ought to speak out about IAM's "business model", which involves collecting cash, pushing agenda (in the form of 'news' or staged 'debates'), offering bogus 'endorsements', and issuing 'studies' for people like Battistelli (bolstering his lies). There's nothing benign about it. IAM is effectively a think tank and even some less senior insiders must have realise it. Several of them left, only to be replaced by relatively young and inexperienced writers. Tim Lince, it should be noted, is still listed as a writer at IAM, but he wrote nothing this year and only 1 (one!) blog post last year. Many writers left and perhaps associating with people Battistelli (as we last noted last night) won't save them but only cause further harm.

Either way, "Pharma and Biotech IP Summit" is an IAM sham. It's sponsored by and dominated by the patent microcosm. It's like a propaganda platform facilitated by Joff Wild and his cohorts. He did the same for UPC (with cash from the EPO's PR firm).

Recent Techrights' Posts

Gemini Links 01/04/2025: Games and More
Links for the day
Why We're Reporting Brett Wilson LLP for Apparently Misusing Their Licence to Protect American Microsofters Who Attack Women
For those who have not been keeping abreast
Stefano Maffulli and His Microsoft-Funded OSI Staff Are Killing the OSI and Killing "Open Source" (All for Money!)
This is far from over
Techrights Headlines as Semaphore
"If you are hearing this, thank you"
 
Ubuntu Slop and FUD Manufactured With LLMs and Funded (by Oneself) 'Studies'
Slop and FUD are ruining the Web
Links 01/04/2025: Apple Fined $162M for Privacy Abuses, Disinformation Online a Growing Concern
Links for the day
Newer Press Reports Confirm That Microsoft Shuts Down 'Hey Hi' (AI) Labs Despite All the Hype
The "hey hi" (AI) bubble is not sustainable
Links 01/04/2025: Mass Layoffs at Eidos and "Microsoft Pulls Back on Data Centers" (Demand Lacking); "Racist and Sexist" Slop From Microsoft
Links for the day
Gemini Links 01/04/2025: XKCDpunk and worldclock.py
Links for the day
50 Years of Sabotage and a Gut Punch to Computer Science (and Science in General)
Will we get back to science-based computing rather than cult-like following?
3 Months in 2025, 4 Waves of Mass Layoffs at Microsoft, Now Offices Shut Down Permanently
"A recent visit by the South China Morning Post confirmed that the office was dark, unoccupied, and had its logo removed."
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Monday, March 31, 2025
IRC logs for Monday, March 31, 2025
Links 31/03/2025: China Tensions, Bombs Falling in Myanmar After Earthquake
Links for the day
Gemini Links 31/03/2025: Falling Out of Love With Tech, Sunsetting openSNP
Links for the day
R.T.O. at IBM in Texas and Atlanta (State of Georgia) Expected as "Soft Layoffs" Catalyst This Coming Year
It also sounds like more IBM layoffs are in the making
Law Firms Can Also Lose Their Licence for Clearly Misusing It
The bottom line is, never made the false assumption that because you can pile up SLAPPs in a docket you will not suffer from bad reputation or even get disbarred
Link between institutional abuse, Swiss jurists, Debianism and FSFE
Reprinted with permission from Daniel Pocock
LLM Slop Piggybacking News About GNU/Linux and Distorting It
new examples
Links 31/03/2025: Press and Democracy Under Further Attacks in the US, Attitudes Towards Slop Sour
Links for the day
Open Source Initiative (OSI) Privacy Fiasco in Detail: The OSI Does Not Respect Anybody's Privacy
The surveillance mafia that bans dissent or key people (even co-founders) with dissenting views
Gemini Links 31/03/2025: More X-Filesposting and Dreaming in Emacs
Links for the day
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Sunday, March 30, 2025
IRC logs for Sunday, March 30, 2025